NEW YORK (GenomeWeb News) – Foundation Medicine reported after the close of the market Wednesday that its third quarter revenues more than doubled year over year and were up 39 percent over the second quarter of this year.

The Cambridge, Mass.-based cancer genomic analysis firm reported total revenues of $8.2 million for the three months ended Sept. 30, up from $3 million in Q3 2012 and $5.9 million in Q2 2013. It beat the consensus Wall Street estimate for revenues of $6.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.